Search the Newsreel

CRISPR Therapeutics AG (CRSP) Stock Forecasts

This article provides an analyst report from Morningstar on CRISPR Therapeutics AG (CRSP), noting that its gene-editing therapy Casgevy is gaining traction despite initial commercial hurdles. The report highlights the company's focus on CRISPR/Cas9-based therapeutics. It also includes various market data and related analyst …

CRISPR Therapeutics AG $CRSP Stock Position Raised by Quantinno Capital Management LP

Quantinno Capital Management LP significantly increased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 613.5% in the first quarter, now owning 47,989 shares valued at $2.28 million. Institutional investors hold 69.2% of the company, and analysts maintain a "Moderate Buy" rating with an average …

Hong Kong Market Midday Commentary | All three major indices declined, with the Hang Seng Tech Index down 1.27%; tech and internet stocks fell, with Kuaishou and JD.com each dropping nearly 3%; biotech stocks rose, as GenScript Biotech surged over 8

US1 Critical Minerals Applies to Quote 7,000 Ordinary Shares Following Option Exercise

US1 Critical Minerals Seeks ASX Quotation for Additional Shares

Scribe Therapeutics (SCTX) grants 14,725 options to Aghazadeh and Avoro entities

Carter's Gains 19.4% in 3 Months as Growth Momentum Supports Upside Case

Carter's, Inc. CRI shares have gained 19.4% over the past three months, outperforming the industry as improving retail trends, international growth and productivity initiatives support the business. The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's …

Scribe Therapeutics (SCTX) ten percent owner Brett Staahl reports stock and option holdings

Scribe Therapeutics (SCTX) ten percent owner Brett Staahl has filed an initial statement of beneficial ownership, reporting 524,336 shares of Common Stock held directly. Additionally, Staahl holds four stock option awards with various exercise prices and expiration dates ranging from 2030 to 2036, covering …

Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing?

Neurocrine Biosciences (NBIX) has commenced a Phase 1 study for its obesity treatment candidate, NBIP 1968, following positive Q2 and H1 2026 financial results. Despite recent stock momentum and a current share price of $163.41, Simply Wall St's analysis suggests the company might be …

Criteo: No Light At The End Of The Tunnel As Top Line Deteriorates (Rating Downgrade)

Criteo (CRTO) has been downgraded to a sell rating following a disappointing Q2 performance and a significant reduction in guidance, indicating it may be a value trap. The company now anticipates a 10% to 12% decline in contribution ex-TAC, with both its Retail Media …

European Lithium (ASX:EUR) Rises As Critical Metals Merger Nears Completion

European Lithium (ASX:EUR) shares rose by 5.76% as its merger with Nasdaq-listed Critical Metals Corp approaches completion. The merger, which aims to transform European Lithium shareholders' holdings from a small-cap lithium explorer into a stake in a larger rare earths and critical minerals developer, …

Apex Critical Metals Corp. (CN:APXC) Stock Slides as Investor Caution Returns to Critical Minerals Sector

Criteo SA (CRTO) Earnings Forecast: Future EPS & Revenue Growth Estimates

Critical Metals Corp (CRML) Earnings Forecast: Future EPS & Revenue Growth Estimates

Hong Kong Stock Market Movement | GenScript Biotech Corporation (01548.HK) Rises Over 8% as AIDD Boosts Demand for Experimental Validation; Institutions Bullish on Strengthened 'Shovel Seller' Thesis

First Trust Advisors LP Raises Stake in Crinetics Pharmaceuticals, Inc. $CRNX

First Trust Advisors LP increased its stake in Crinetics Pharmaceuticals (CRNX) by 54.9% in the first quarter, now holding 51,365 shares valued at $1.87 million. Despite insider stock sales, the company reported strong Q1 earnings, beating revenue estimates by 2336.9% year-over-year. Analysts have a …

Crinetics Pharmaceuticals Inc (CRNX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study

Acrivon Therapeutics, Inc. announced the advancement of ACR-2316, a WEE1/PKMYT1 inhibitor, into the randomized dose expansion portion of its Phase 1/2 study. The decision follows observed clinical activity and a favorable safety profile during dose escalation, including durable responses in heavily pretreated lung cancer …

Carter's (CRI) Posts Stronger Earnings And New Guidance, Is It Still Below Fair Value?

Acrivon Therapeutics Inc (ACRV) Stock News Today

This article provides current stock information for Acrivon Therapeutics Inc (ACRV), including its market capitalization and recent stock performance. It notes a slight decrease in stock price and indicates that more news, earnings, and analyst ratings will be available soon. The page serves as …

Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Cetera Investment Advisers

Cetera Investment Advisers significantly increased its stake in Neurocrine Biosciences (NBIX) by 50.1% in the first quarter, now owning 20,245 shares valued at $2.67 million. Institutional investors hold 92.59% of NBIX. Despite insider sales totaling over $62 million in the past quarter, analysts maintain …

CRISPR Therapeutics (CRSP) Earnings Drew Fresh Interest, Is The Stock Below Fair Value?

CRISPR Therapeutics (CRSP) reported improved Q2 2026 results with higher revenue and a reduced net loss, leading to a short-term stock rebound. Despite mixed long-term performance, a discounted cash flow (DCF) model suggests the stock is significantly undervalued at $53.52 compared to a fair …

Neurocrine Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2026-08-07

This article announces that Neurocrine Biosciences, Inc. (NBIX) has published its slide deck in conjunction with its Q2 2026 earnings call. The earnings call presentation was made on August 7, 2026. The article was written by the Seeking Alpha Transcripts team, which regularly publishes …

Neurocrine Biosciences, Inc. $NBIX Stake Boosted by PKO BP BANKOWY Universal Pension Society JSC

PKO BP BANKOWY Universal Pension Society JSC significantly increased its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 23.1% in the second quarter, now holding 170,802 shares valued at $28.8 million. This move highlights continued institutional investor interest, with several other hedge funds also boosting their …

ETFs Investing in Neurocrine Biosciences, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Neurocrine Biosciences, Inc. The list, sorted by market value, provides details such as market value, weight, issuer, management style, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV …

How Stronger Q2 Results and New Equity Capacity Will Impact Neurocrine Biosciences (NBIX) Investors

Neurocrine Biosciences recently reported strong Q2 2026 results, with significant revenue and net income, alongside a new equity shelf registration tied to an ESOP offering. This dual development highlights the company's efforts to strengthen employee ownership and financial flexibility. The article discusses how these …

CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen

Wall Street Zen has upgraded CRISPR Therapeutics (CRSP) from a "Sell" to a "Hold" rating, while the broader analyst consensus remains a "Moderate Buy" with an average target price of $68.06. Despite a recent 3.6% increase in share price, the company reported a quarterly …

E.W. Scripps (NASDAQ:SSP) Announces Quarterly Earnings Results, Beats Estimates By $0.19 EPS

Critical Metals Corp (CRML) Stock Analysis & Forecast

This article provides an analysis and forecast for Critical Metals Corp (CRML) stock, highlighting its current market performance with a significant gain. It references a market recap discussing AI trends, geopolitical tensions, and specific company news like Qualcomm's AI surge and Microsoft's OpenAI unbundling, …

Carter's (CRI) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Friday, July 31, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer and President - Sharon Price JohnChief Financial Officer and Chief Operating Officer - Richard WestenbergerChief Retail and Digital Officer - Allison PetersonVice President, Investor Relations …

Crinetics Pharmaceuticals (NASDAQ: CRNX) sees 1.4% stake reported by FMR LLC

FMR LLC and Abigail P. Johnson have reported an amended passive investment disclosure for Crinetics Pharmaceuticals (CRNX) via a Schedule 13G/A filing. FMR LLC holds beneficial ownership of 1,439,890.88 shares, representing 1.4% of the common stock outstanding, with nearly all shares holding sole voting …

Crinetics Pharmaceuticals, Inc. $CRNX Shares Bought by Glenmede Trust Co. NA

Glenmede Trust Co. NA increased its stake in Crinetics Pharmaceuticals (NASDAQ:CRNX) by 72.6% in the first quarter, now holding 29,245 shares valued at $1.06 million. Despite some insider selling, institutional investors own 98.51% of the company. Crinetics Pharmaceuticals reported better-than-expected Q1 earnings with a …

E.W. Scripps Q2 2026 Loss Widens to -$12.68/Share, Revenue Down 9%

Should You Investigate Genscript Biotech Corporation (HKG:1548) At HK$22.98?

Michael Komasinski Sells 15,559 Shares of Criteo (NASDAQ:CRTO) Stock

Criteo CEO Michael Komasinski sold 15,559 shares of CRTO stock worth approximately $268,082 to cover tax obligations related to vested equity awards, reducing his direct stake by 4.31%. Despite the insider sale, Criteo's stock rose 4.4% to $18.36, and the company reported stronger-than-expected Q2 …

Acrivon Therapeutics, Inc. expected to post a loss of 50 cents a share - Earnings Preview

Acrivon Therapeutics, Inc. is projected to report a loss of 50 cents per share in its upcoming earnings. This information is provided as an earnings preview. The article encourages readers to access the full report for more details.